Boston Scientific Co. (NYSE:BSX) Shares Bought by Huntington National Bank

Huntington National Bank increased its stake in Boston Scientific Co. (NYSE:BSX) by 7.6% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,198,556 shares of the medical equipment provider’s stock after purchasing an additional 84,830 shares during the quarter. Huntington National Bank owned 0.08% of Boston Scientific worth $100,439,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in the stock. Bouvel Investment Partners LLC increased its holdings in Boston Scientific by 1.6% during the 3rd quarter. Bouvel Investment Partners LLC now owns 45,148 shares of the medical equipment provider’s stock valued at $3,783,000 after acquiring an additional 702 shares in the last quarter. Mizuho Securities Co. Ltd. purchased a new position in Boston Scientific during the 3rd quarter valued at about $84,000. Saturna Capital Corp increased its holdings in Boston Scientific by 1.5% during the 3rd quarter. Saturna Capital Corp now owns 26,500 shares of the medical equipment provider’s stock valued at $2,221,000 after acquiring an additional 400 shares in the last quarter. Aptus Capital Advisors LLC increased its holdings in Boston Scientific by 5.5% during the 3rd quarter. Aptus Capital Advisors LLC now owns 9,969 shares of the medical equipment provider’s stock valued at $835,000 after acquiring an additional 520 shares in the last quarter. Finally, Aigen Investment Management LP acquired a new stake in shares of Boston Scientific during the 3rd quarter worth about $567,000. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the stock. Wells Fargo & Company raised their price target on shares of Boston Scientific from $87.00 to $98.00 and gave the stock an “overweight” rating in a research note on Thursday, October 24th. Evercore ISI raised their price target on shares of Boston Scientific from $82.00 to $90.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 1st. Canaccord Genuity Group raised their target price on shares of Boston Scientific from $88.00 to $98.00 and gave the stock a “buy” rating in a research report on Monday, October 21st. Robert W. Baird raised their target price on shares of Boston Scientific from $90.00 to $91.00 and gave the stock an “outperform” rating in a research report on Thursday, July 25th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Boston Scientific in a research report on Thursday, October 31st. Four research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $93.39.

Boston Scientific Price Performance

Shares of Boston Scientific stock opened at $88.77 on Thursday. The company has a current ratio of 1.48, a quick ratio of 1.02 and a debt-to-equity ratio of 0.44. The company’s 50-day moving average price is $84.89 and its two-hundred day moving average price is $79.26. Boston Scientific Co. has a 52 week low of $53.56 and a 52 week high of $89.30. The stock has a market cap of $130.83 billion, a PE ratio of 73.36, a price-to-earnings-growth ratio of 2.61 and a beta of 0.79.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, October 23rd. The medical equipment provider reported $0.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.59 by $0.04. The firm had revenue of $4.21 billion for the quarter, compared to the consensus estimate of $4.04 billion. Boston Scientific had a return on equity of 17.23% and a net margin of 11.26%. The business’s revenue for the quarter was up 19.3% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.50 EPS. As a group, sell-side analysts anticipate that Boston Scientific Co. will post 2.46 EPS for the current fiscal year.

Insider Activity

In related news, EVP Wendy Carruthers sold 6,983 shares of the stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $81.70, for a total value of $570,511.10. Following the transaction, the executive vice president now owns 37,468 shares in the company, valued at approximately $3,061,135.60. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In other news, CEO Michael F. Mahoney sold 162,777 shares of the firm’s stock in a transaction on Monday, October 7th. The shares were sold at an average price of $84.63, for a total value of $13,775,817.51. Following the sale, the chief executive officer now owns 1,572,096 shares in the company, valued at approximately $133,046,484.48. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Wendy Carruthers sold 6,983 shares of the firm’s stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $81.70, for a total transaction of $570,511.10. Following the completion of the sale, the executive vice president now owns 37,468 shares in the company, valued at approximately $3,061,135.60. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 309,270 shares of company stock worth $26,196,718 in the last 90 days. Company insiders own 0.50% of the company’s stock.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.